Connect with us

Health

Vitamin and Minerals Global Market to Reach $24.69 Billion by 2026

Published

on

DUBLIN /PRNewswire/ — The “Vitamin and Minerals Global Market Report 2022: By Type, By Application, By Distribution, By End-User” report has been added to  ResearchAndMarkets.com’s offering.

The global vitamin and minerals market is expected to grow from $20.16 billion in 2021 to $21.37 billion in 2022 at a compound annual growth rate (CAGR) of 6.0%. The market is expected to reach $24.69 billion in 2026 at a CAGR of 3.7%.

North America was the largest region in the vitamins and minerals supplements market in 2021. Middle East is expected to be the largest growing region in the forecast period. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The growing use of dietary supplements in the modern lifestyle is a key factor driving the growth of the vitamins and mineral supplement market. Nutrition plays an important role in maintaining immune system balance, and supplementation with the micronutrients such as vitamins C and D, Zinc and omega fatty acids within recommended upper safety limits is a safe, effective and low-cost strategy to help support optimal immune function in patients fighting COVID-19 and other respiratory tract diseases.

In the case of COVID-19 patients, a variety of high-protein and fibre foods, including cookies, bread and rolls, have been developed by the Indian Research Institute. For example, to improve children’s immunity, dietary supplement company Avida Health has launched a chocolate ball functional food in Singapore. A nutritional focus on the immune system could help minimize the impact of the current COVID-19 pandemic and other infections. Therefore, the implementation of dietary supplements in the lifestyle is expected to drive the growth of the vitamins and mineral supplement market.

The consumer preference moving towards organic supplements is a key trend in the vitamins and mineral supplement market. There was a suggested transition towards vegan & organic food in 2020, and this trend will shortly become a lifestyle for many people as COVID-19 is taking the world by storm.

As a lot of people globally believe that the COVID crisis is associated with the consumption of animal meat, people will become more cautious of the food they consume and this can result in a significant rise in the demand for organic and vegan food products. Many small and medium enterprises have started to promote plant-based goods and diets in the product space. The coronavirus pandemic is accelerating the trend for organic food supplements.

Scope
Markets Covered:
1) By Type: Multivitamin; Single Vitamin; Multi Mineral; Single Mineral
2) By Application: Energy And Weight Management; General Health; Bone And Joint Health; Gastrointestinal Health; Immunity; Cardiac Health; Diabetes; Anti-Cancer; Others
3) By Distribution Channel: Pharmacies ANd Drug Stores; Supermarkets And Hypermarkets; Online Channels
4) By End-User: Adults; Geriatric; Pregnant Women; Children; Infants

Key Topics Covered:

1. Executive Summary

2. Vitamins and Mineral Supplement Market Characteristics

3. Vitamins and Mineral Supplement Market Trends And Strategies

4. Impact Of COVID-19 On Vitamins and Mineral Supplement

5. Vitamins and Mineral Supplement Market Size And Growth

6. Vitamins and Mineral Supplement Market Segmentation

7. Vitamins and Mineral Supplement Market Regional And Country Analysis

8. Asia-Pacific Vitamins and Mineral Supplement Market

9. China Vitamins and Mineral Supplement Market

10. India Vitamins and Mineral Supplement Market

11. Japan Vitamins and Mineral Supplement Market

12. Australia Vitamins and Mineral Supplement Market

13. Indonesia Vitamins and Mineral Supplement Market

14. South Korea Vitamins and Mineral Supplement Market

15. Western Europe Vitamins and Mineral Supplement Market

16. UK Vitamins and Mineral Supplement Market

17. Germany Vitamins and Mineral Supplement Market

18. France Vitamins and Mineral Supplement Market

19. Eastern Europe Vitamins and Mineral Supplement Market

20. Russia Vitamins and Mineral Supplement Market

21. North America Vitamins and Mineral Supplement Market

22. USA Vitamins and Mineral Supplement Market

23. South America Vitamins and Mineral Supplement Market

24. Brazil Vitamins and Mineral Supplement Market

25. Middle East Vitamins and Mineral Supplement Market

26. Africa Vitamins and Mineral Supplement Market

27. Vitamins and Mineral Supplement Market Competitive Landscape And Company Profiles

28. Vitamins and Mineral Supplement Pipeline Analysis

29. Key Mergers And Acquisitions In The Vitamins and Mineral Supplement Market

30. Vitamins and Mineral Supplement Market Future Outlook and Potential Analysis

Companies Mentioned

Advertisement
  • Salus Haus
  • Pfizer
  • Daiichi Sankyo
  • AMWAY
  • Eisai
  • Sanofi
  • GNC
  • CSPC Pharmaceutical Group
  • DSM
  • Otsuka Holdings Co. Ltd.
  • Puritan’s Pride
  • Pharmavite
  • Jamieson
  • Webber Naturals
  • Hainan Yangshengtang
  • Nature’s Bounty
  • CCMP Capital
  • Pharmavite
  • Suntory Holdings Ltd.
  • Glanbia plc.
  • Glaxosmithkline plc.
  • Abbott Laboratories
  • Bayer AG
  • Puritan’s Pride
  • General Nutrition Centers inc.
  • Webber Naturals
  • CSPC Pharmaceutical Group
  • Hainan Yangshengtang

For more information about this report visit https://www.researchandmarkets.com/r/9uwxg

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

Health

Coordination of COVID-19 Vaccine Clinical Trials Produces a ‘Treasure Trove’ of Data and a Model for the Future

Published

on

Harmonized approach and vast database of trial participants could bolster future research well beyond SARS-CoV-2

Newswise — SEATTLE – The federally funded COVID-19 Prevention Network (CoVPN), headquartered at Fred Hutchinson Cancer Center in Seattle, was instrumental in the rapid development of safe, effective and lifesaving COVID-19 vaccines during earlier phases of the pandemic.

Its vital work to expedite Phase 3 COVID-19 vaccine clinical trials also resulted in a highly collaborative and harmonized approach that can serve as a national and even international model for major research initiatives while also guiding responses to future public health emergencies.

That’s the overarching theme from a new study published Monday, Jan. 23, in JAMA Network Open.

“Our success, which depended entirely on the investments into HIV vaccine research, can be replicated for other important research initiatives and highlights the importance of investments that boost pandemic preparedness for years to come,” explained James G. Kublin, MD, MPH, executive director of CoVPN and senior and corresponding author of the study.

Additionally, he and his colleagues, including  Alfredo Mena Lora, MD, assistant professor of medicine at the University of Illinois at Chicago, and co-first author Jessica Long, PhD, MPH, a postdoctoral fellow at the University of Washington Department of Medicine in Seattle, noted that the COVID-19 clinical trials produced a vast database of critical information that could help researchers answer pressing questions about this novel virus moving forward. 

“The harmonization of data across trials is a new strategy that will set the standard for collaboration in future clinical trials,” said Mena Lora. 

Advertisement

The authors detail how CoVPN was able to help secure authorized vaccines in less than a year by the National Institute of Allergy and Infectious Diseases at the National Institutes of Health as part of Operation Warp Speed. Its mission was, and continues to be, to support the rapid development of vaccines for the U.S. and global populations by coordinating and implementing Phase 3 trials for COVID-19 vaccine candidates.

CoVPN officials were able to leverage existing resources, including clinical and laboratory infrastructure, community partnerships and research expertise, to get clinical sites to quickly pivot to conduct the vaccine trials as soon as investigational products were ready for Phase 3 testing.

“The CoVPN approach drew on years of experience and infrastructure from partnering networks and institutions, which not only allowed for rapid rollout of the trials, but also contributed to broader representation of trial participants,” said Long.

Overall, CoVPN deployed five Phase 3 clinical trials involving more than 136,000 participants to test the safety and effectiveness of COVID-19 vaccines. While doing so, it implemented several innovative procedures that were essential to its ultimate success. These included:

  • Harmonized study designs that were similar in relative size, number of endpoints and time to analysis.
  • A model that accelerated vaccine development by allowing phases to occur in parallel rather than sequentially. For example, vaccine manufacturing and scale-up were greenlighted while the trials were ongoing in anticipation of meeting efficacy targets.
  • Establishment of a single Data Safety Monitoring Board for review and oversight of all vaccine studies.
  • Targeted outreach and enrollment efforts supported by an online screening registry to ensure broad and diverse representation among study participants. Extensive engagement was conducted with communities and community leaders to build and enhance trust in the science to help enroll more Black, Indigenous and people of color (BIPOC) volunteers who are historically underrepresented in clinical trials.
  • A cross-platform approach that led to harmonization of data collection across trials and the ability to analyze data from all studies.

“This unique, cross-platform concept allowed for sharing of data from all of the studies and helped bridge gaps in understanding so we could better answer key research questions and guide policy decisions,” explained Kublin, who’s also a principal staff scientist at Fred Hutch. 

Larry Corey, MD, an internationally renowned expert in vaccine development, and principal co-investigator of CoVPN, believes the success of COVID-19 clinical trials should be thought of as an important model for developing vaccines for significant infectious diseases globally.

“Harmonizing study design, enrollment, clinical endpoints and methods for follow-up could very well become best practices that shape the future landscape of major research initiatives and pandemic responses,” he said. 

Advertisement

Kublin and colleagues regard the vast database from more than 130,000 trial participants, including over 2,500 with documented COVID-19 cases, as a “treasure trove” of data that could help unlock mysteries about the virus. For example, they noted that the pooled data from five trials can help address specific questions such as:

  • How effective are vaccines for at-risk groups?
  • Can vaccines have an impact on long COVID?
  • Are safety, immunogenicity and vaccine efficacy different in special populations, such as people living with HIV?
  • What impact do chronic health conditions have on vaccine efficacy or protection duration?
  • What are the impacts of variants on both the population at large and within special communities?

Additional CoVPN publications planned for the months ahead will address many of these topics. Researchers who have ideas for further investigation and want to collaborate with CoVPN can find more information here.

Source: Covid-19 Prevention Network (CoVPN)

Continue Reading

Health

Observing World Cancer Day

Published

on

World Cancer Day is an international day marked on 4 February to raise awareness of cancer and to encourage its preventiondetection, and treatment. World Cancer Day is led by the Union for International Cancer Control (UICC) to support the goals of the World Cancer Declaration, written in 2008. The primary goal of World Cancer Day is to significantly reduce illness and death caused by cancer and is an opportunity to rally the international community to end the injustice of preventable suffering from cancer. The day is observed by the United Nations.

World Cancer Day targets misinformation, raises awareness, and reduces stigma. Multiple initiatives are run on World Cancer Day to show support for those affected by cancer. One of these movements are #NoHairSelfie, a global movement to have “hairticipants” shave their heads either physically or virtually to show a symbol of courage for those undergoing cancer treatment. Images of participants are then shared all over social media. Hundreds of events around the world also take place. (wikipedia)

https://stmdailynews.com/category/lifestyle/health-and-wellness/health/

Advertisement
Continue Reading

FDA CDC News

FDA Concludes that Existing Regulatory Frameworks for Foods and Supplements are Not Appropriate for Cannabidiol, Will Work with Congress on a New Way Forward

Published

on

Statement From:Janet Woodcock, M.D.
Principal Deputy Commissioner – Office of the Commissioner

January 26, 2023

Given the growing cannabidiol (CBD) products market, the U.S. Food and Drug Administration convened a high-level internal working group to explore potential regulatory pathways for CBD products. Today we are announcing that after careful review, the FDA has concluded that a new regulatory pathway for CBD is needed that balances individuals’ desire for access to CBD products with the regulatory oversight needed to manage risks. The agency is prepared to work with Congress on this matter. Today, we are also denying three citizen petitions that had asked the agency to conduct rulemaking to allow the marketing of CBD products as dietary supplements.  

The use of CBD raises various safety concerns, especially with long-term use. Studies have shown the potential for harm to the liver, interactions with certain medications and possible harm to the male reproductive system. CBD exposure is also concerning when it comes to certain vulnerable populations such as children and those who are pregnant. 

A new regulatory pathway would benefit consumers by providing safeguards and oversight to manage and minimize risks related to CBD products. Some risk management tools could include clear labels, prevention of contaminants, CBD content limits, and measures, such as minimum purchase age, to mitigate the risk of ingestion by children. In addition, a new pathway could provide access and oversight for certain CBD-containing products for animals.

Advertisement

The FDA’s existing foods and dietary supplement authorities provide only limited tools for managing many of the risks associated with CBD products. Under the law, any substance, including CBD, must meet specific safety standards to be lawfully marketed as a dietary supplement or food additive. 

The working group, which I chair, has closely examined studies related to the CBD-based drug Epidiolex, published scientific literatureinformation submitted to a public docket, as well as studies both conducted and commissioned by the agency. Given the available evidence, it is not apparent how CBD products could meet safety standards for dietary supplements or food additives. For example, we have not found adequate evidence to determine how much CBD can be consumed, and for how long, before causing harm. Therefore, we do not intend to pursue rulemaking allowing the use of CBD in dietary supplements or conventional foods. 

CBD also poses risks to animals, and people could be unknowingly exposed to CBD through meat, milk and eggs from animals fed CBD. Because it is not apparent how CBD products could meet the safety standard for substances in animal food, we also do not intend to pursue rulemaking allowing the use of CBD in animal food. A new regulatory pathway could provide access and oversight for certain CBD-containing products for animals.

The FDA will continue to take action against CBD and other cannabis-derived products to protect the public, in coordination with state regulatory partners, when appropriate. We will remain diligent in monitoring the marketplace, identifying products that pose risks and acting within our authorities. The FDA looks forward to working with Congress to develop a cross-agency strategy for the regulation of these products to protect the public’s health and safety.

Continue Reading

Subscribe to the SPR Newsletter

DON’T MISS A DINK

Be the first to know when the latest episode of Sleeve's Senior Pickleball Report is released on YouTube and more...

We don’t spam! Read our privacy policy for more info.

Advertisement pet, pets, dog, dogs, supplements, Pawlife, Pawlife Pets, dog health, dog treats, all natural, wellness product, dog supplements, all-natural
Advertisement

Want more stories 👋
News you Can Use, "THIS MOMENT!"

Sign up to receive awesome articles directly to your inbox, every month.

We don’t spam! Read our privacy policy for more info.

Advertisement

The Latest from TNC Network: TNC Network News

Trending

%d bloggers like this: